The North America Lung Cancer Therapeutics Market was valued at USD 6.60 Billion in 2025 and is expected to reach USD 10.59 Billion by 2033, growing at a CAGR of 6.1% (2026-2033).

The Middle East and Africa Lung Cancer Therapeutics Market was valued at USD 1.54 Billion in 2025 and is expected to reach USD 2.89 Billion by 2033, growing at a CAGR of 8.2% (2026-2033).

The Europe Lung Cancer Therapeutics Market was valued at USD 2.33 Billion in 2025 and is expected to reach USD 3.97 Billion by 2033, growing at a CAGR of 6.9% (2026-2033).

The Global Lung Cancer Screening Software Market was valued at USD 47.38 Billion in 2024 and is expected to reach USD 195.75 Billion by 2032, growing at a CAGR of 19.4% (2025-2032).

The North America Lung Cancer Therapeutics Market was valued at USD 6.60 Billion in 2025 and is expected to reach USD 10.59 Billion by 2033, growing at a CAGR of 6.1% (2026-2033).

The Middle East and Africa Lung Cancer Therapeutics Market was valued at USD 1.54 Billion in 2025 and is expected to reach USD 2.89 Billion by 2033, growing at a CAGR of 8.2% (2026-2033).

The Europe Lung Cancer Therapeutics Market was valued at USD 2.33 Billion in 2025 and is expected to reach USD 3.97 Billion by 2033, growing at a CAGR of 6.9% (2026-2033).

The Asia-Pacific Lung Cancer Therapeutics Market was valued at USD 1.47 Billion in 2024 and is expected to reach USD 2.75 Billion by 2032, growing at a CAGR of 8.1% (2025-2032).

The Global Lung Cancer Therapeutics Market was valued at USD 33.19 Billion in 2024 and is expected to reach USD 73.29 Billion by 2032, growing at a CAGR of 10.41% (2025-2032).

The Global Lung Cancer Surgery Market was valued at USD 0.00 Billion in 2022 and is expected to reach USD 5.12 Billion by 2029, growing at a CAGR of 5.5% (2023-2029).